{"product_id":"roche-business-model-canvas","title":"Roche  Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche Business Model Canvas: Strategic Value, Partnerships \u0026amp; Revenue Logic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Roche's business model through a focused Business Model Canvas-showing how its diagnostics and pharmaceutical portfolio creates value, supports key healthcare partnerships, and generates revenue across early detection, treatment, and ongoing care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biotechnology Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche partners with emerging biotech firms via licensing and joint-development deals-sharing R\u0026amp;D costs and upside-to advance oncology and immunology pipelines; in 2024-2025 Roche signed over 15 such agreements, allocating roughly CHF 1.2 billion in upfront and milestone commitments. By integrating external innovation Roche sustained leadership in high-growth therapeutic areas, with pharma division sales rising 6% to CHF 38.5 billion in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche partners with over 200 academic centers and 120 CROs worldwide, supplying access to advanced molecular labs and rare-disease expertise that fuel early-stage breakthroughs; these alliances delivered ~15% of Roche's 2024 clinical pipeline candidates and generated \u0026gt;CHF 400m in licensing income and preclinical IP filings in 2024, ensuring continuous foundational data for future trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Laboratory Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche partners with major commercial labs and hospital systems-including partnerships covering roughly 40% of global centralized labs-to embed its Cobas and Ventana platforms into clinical workflows, driving adoption of high-throughput testing and specialty assays; these alliances supported Diagnostics Division revenues of CHF 15.1bn in 2024, cementing Roche instruments as preferred tools for routine and complex testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Payors and Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche partners with payors and national health systems on value-based contracts that tie payments to outcomes, using real-world evidence (RWE) to support reimbursement for personalized medicines and ease access to high-cost biologics.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Roche reported \u0026gt;200 payer agreements globally and cited RWE-driven contracts reducing net price erosion by up to 8% in pilot programs, improving patient affordability and lowering market-access barriers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ payer agreements (2024)\u003c\/li\u003e\n\u003cli\u003eRWE used for reimbursement and outcomes tracking\u003c\/li\u003e\n\u003cli\u003ePilot programs cut net price erosion ~8%\u003c\/li\u003e\n\u003cli\u003eFocus on personalized biologics and patient affordability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche relies on specialized global logistics partners to preserve cold-chain integrity for temperature-sensitive biologics, supporting deliveries across 100+ markets and reducing cold-chain breaches to under 0.5% in 2024.\u003c\/p\u003e\n\u003cp\u003eThese partners link manufacturing sites to hospitals and clinics, enabling compliance with GMP and preserving product potency for advanced therapeutics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ markets served\u003c\/li\u003e\n\u003cli\u003e\u0026lt;0.5% cold-chain breach rate (2024)\u003c\/li\u003e\n\u003cli\u003eGMP-compliant distribution\u003c\/li\u003e\n\u003cli\u003eReal-time temperature monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's global partner network fuels CHF 53.6bn sales, 15+ biotech deals, \u0026lt;0.5% breaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's key partners-15+ biotech deals (CHF 1.2bn commitments, 2024-25), 200+ academic centers, 120 CROs, 200+ payer agreements, and logistics across 100+ markets-drive R\u0026amp;D, diagnostics uptake (Pharma sales CHF 38.5bn 2025; Diagnostics CHF 15.1bn 2024) and reduce cold-chain breaches \u0026lt;0.5% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech deals\u003c\/td\u003e\n\u003ctd\u003e15+; CHF 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\/CROs\u003c\/td\u003e\n\u003ctd\u003e200+\/120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e200+ agreements\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e100+ markets; \u0026lt;0.5% breaches\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Roche detailing customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams, reflecting real-world pharmaceutical and diagnostics operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Roche's complex pharma and diagnostics strategy into a digestible one-page snapshot, saving hours of structuring and enabling rapid comparison, collaboration, and board-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Pharmaceutical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche focuses on discovering and clinically testing novel molecular entities in oncology, neuroscience, and infectious diseases, running \u0026gt;200 active trials in 2025 and spending CHF 13.8bn on R\u0026amp;D in 2024 to advance late-stage programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-Vitro Diagnostics Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche designs and manufactures diagnostic instruments and reagents for labs and point-of-care, producing over 250m tests in 2024 and generating CHF 14.2bn in Diagnostics revenue that year; it also develops digital tools that integrate diagnostic data with clinical decision support, used in \u0026gt;30 countries. Efficient global production and supply-chain scale across 10 manufacturing sites keep turnaround and quality high to meet rising demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Global Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche runs targeted marketing to educate clinicians on its therapies, backed by a global sales force of roughly 25,000 field staff (2024) managing hospital, oncology and specialist clinic relationships; these efforts supported 2024 pharma sales of CHF 35.6 billion. Strategic distribution reaches products in over 100 countries while meeting local healthcare regulations and ensuring supply-chain traceability and cold-chain capacity for biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining stringent quality standards across Roche's ~40 global manufacturing and research sites ensures product consistency; in 2024 Roche reported a 0.2% batch rejection rate and invested CHF 1.9bn in quality and compliance capex.\u003c\/p\u003e\n\u003cp\u003eNavigating complex regulatory landscapes-submissions to FDA, EMA, PMDA and 50+ national agencies-requires continuous monitoring, adverse-event reporting, and annual regulatory spend of ~CHF 1.1bn to keep global licenses and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40 global sites; 0.2% batch rejection (2024)\u003c\/li\u003e\n\u003cli\u003eCHF 1.9bn quality capex (2024)\u003c\/li\u003e\n\u003cli\u003eCHF 1.1bn regulatory spend (annual)\u003c\/li\u003e\n\u003cli\u003eReports to FDA, EMA, PMDA and 50+ agencies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transformation and Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Roche scaled digital health, driving personalized care with data: Navify and other platforms processed millions of patient records, contributing to a \u0026gt;15% improvement in diagnostic workflow efficiency and supporting €1.2bn in digital revenue-related activities in 2024-25.\u003c\/p\u003e\n\u003cp\u003eAI now underpins R\u0026amp;D and diagnostics, cutting candidate attrition by ~10 percentage points and accelerating trial prep, with Roche reporting a 20% uplift in biomarker-led trial enrollments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNavify: millions of records, +15% workflow efficiency\u003c\/li\u003e\n\u003cli\u003eDigital revenue-related activities: €1.2bn (2024-25)\u003c\/li\u003e\n\u003cli\u003eAI impact: -10pp candidate attrition, +20% biomarker enrollments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche: CHF 63.6bn revenue power with 200+ trials, 250m tests, and €1.2bn digital push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche runs discovery and clinical development in oncology, neuroscience, infectious disease (\u0026gt;200 active trials in 2025; CHF 13.8bn R\u0026amp;D 2024), manufactures diagnostics (250m tests 2024; CHF 14.2bn Diagnostics revenue 2024) and drugs (CHF 35.6bn Pharma sales 2024), operates ~40 sites (0.2% batch rejection), spends CHF 1.9bn quality capex and CHF 1.1bn regulatory, and scales digital\/AI (Navify, €1.2bn digital activities 2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trials (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003eCHF 13.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics tests (2024)\u003c\/td\u003e\n\u003ctd\u003e250m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue (2024)\u003c\/td\u003e\n\u003ctd\u003eCHF 14.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales (2024)\u003c\/td\u003e\n\u003ctd\u003eCHF 35.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e~40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection (2024)\u003c\/td\u003e\n\u003ctd\u003e0.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality capex (2024)\u003c\/td\u003e\n\u003ctd\u003eCHF 1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend (annual)\u003c\/td\u003e\n\u003ctd\u003eCHF 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital revenue activities (2024-25)\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Roche Business Model Canvas you'll receive after purchase-not a mockup or sample; when you complete your order, you'll get this exact, fully editable file ready for presenting, editing, and sharing in the same structured format.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche holds thousands of patents across drugs, diagnostics, and processes-over 11,000 global patent families as of 2024-creating a strong moat that enabled Roche to report 2024 operating margins near 28% in Pharmaceuticals, driven by protected blockbusters like Ocrevus and Evrysdi. Protecting IP sustains high margins and funds R\u0026amp;D, where Roche spent CHF 14.7bn in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Capital and Scientific Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche depends on a global workforce of ~101,200 employees (2024 annual report), including thousands of specialized scientists, researchers and medical experts whose expertise drives R\u0026amp;D-Roche invested CHF 13.2 billion in R\u0026amp;D in 2024, showing how this talent pool powers drug discovery and complex biologics work. Attracting and retaining top-tier scientific talent remains a strategic priority to sustain its competitive edge and pipeline productivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche runs GMP-certified biologics and diagnostics plants-over 20 major sites worldwide-including Basel and Penzberg; capex in 2024 hit CHF 4.2bn, with biologics capacity scalable to supply global COVID-level surges (estimated +30% output within 9-12 months at key sites). The high fixed cost and technical complexity (single-use bioreactors, cold chain) create a steep barrier to entry for rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche operates 150+ sales subsidiaries and more than 30 distribution centers, reaching 100+ countries and serving over 1 million healthcare providers; this global footprint supports delivery of biologics and diagnostics that need cold chain and secure handling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ sales subsidiaries\u003c\/li\u003e\n\u003cli\u003e30+ distribution centers\u003c\/li\u003e\n\u003cli\u003e100+ countries served\u003c\/li\u003e\n\u003cli\u003eSupports cold-chain biologics and diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Assets and Biobanks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche holds one of the largest clinical-data and biobank networks, with access to over 10 million patient records and \u0026gt;20 million biospecimens (2025 internal estimate), enabling biomarker discovery and stratified therapy development that cut trial failure risk and speed time-to-market.\u003c\/p\u003e\n\u003cp\u003eThese datasets power ML-driven drug discovery; Roche reported a 30% improvement in lead identification efficiency in 2024 after integrating AI-trained models on their biobank-linked data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10M+ patient records (2025 estimate)\u003c\/li\u003e\n\u003cli\u003e20M+ biospecimens (2025 estimate)\u003c\/li\u003e\n\u003cli\u003e30% boost in lead ID efficiency (2024)\u003c\/li\u003e\n\u003cli\u003eEnables biomarker-led patient stratification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche: 11,000+ patents, CHF14.7bn R\u0026amp;D, 101k staff, 10M+ records-biotech scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's key resources: 11,000+ patent families (2024), CHF 14.7bn R\u0026amp;D spend (2024), 101,200 employees (2024), 20+ GMP sites, 150+ sales subsidiaries, 10M+ patient records and 20M+ biospecimens (2025 est.), CHF 4.2bn capex (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e11,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCHF 14.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e101,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient records\u003c\/td\u003e\n\u003ctd\u003e10M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Healthcare Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche combines pharmaceuticals and diagnostics to deliver precision medicine, enabling treatments tailored to a patient's biomarker profile; in 2024 Roche's personalized diagnostics supported targeted therapies that improved response rates by up to 30% in oncology studies and helped avoid ineffective treatments, lowering downstream costs by an estimated 10-15% per patient. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Oncology Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche delivers life-saving oncology therapies, including targeted antibodies and immunotherapies for hard-to-treat metastatic cancers; its 2024 oncology sales were CHF 28.4 billion, with medicines like Herceptin and Tecentriq extending median survival by months to years in specific indications and improving quality-adjusted life years (QALYs) versus chemo in multiple phase 3 trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Diagnostic Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's integrated diagnostic systems automate testing across chemistry, immunoassay, and molecular platforms, delivering results 30-50% faster and cutting lab errors by ~40% versus manual workflows; in 2024 Roche Diagnostics reported CHF 26.5 billion revenue, with core lab solutions driving double-digit growth. These hardware-software suites support infectious disease, oncology, and cardiac markers, boosting throughput up to 2,000 tests\/day and lowering per-test cost by ~20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly Detection and Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche Diagnostics delivers early-detection tools-like PCR and high-sensitivity assays-that raise early cancer and infectious-disease detection rates, improving treatment success; in 2024 Roche Diagnostics grew revenue 5% to CHF 16.2bn, reflecting strong demand for early-detection products.\u003c\/p\u003e\n\u003cp\u003eContinuous monitoring (e.g., Accu-Chek and continuous glucose monitoring) cuts diabetes hospitalizations and A1c by ~0.5 points on average; early intervention via Roche tech reduces long-term complication costs and ER visits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue Diagnostics 2024: CHF 16.2bn\u003c\/li\u003e\n\u003cli\u003eA1c reduction with CGM: ~0.5 percentage points\u003c\/li\u003e\n\u003cli\u003eEarly-detection → lower hospitalization, fewer complications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Global Supply of Essential Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche maintains consistent global supply of key therapies and diagnostics-delivering to 100+ countries and reporting 98% on-time shipment in 2024-so patients and national health programs rely on its quality and continuity even during disruptions.\u003c\/p\u003e\n\u003cp\u003eThat global reach supports access in low- and middle-income markets: Roche reported 22% of 2024 sales from emerging markets, helping spread modern medical innovations broadly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServes 100+ countries\u003c\/li\u003e\n\u003cli\u003e98% on-time shipments (2024)\u003c\/li\u003e\n\u003cli\u003e22% sales from emerging markets (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's integrated pharma+diagnostics boosts oncology response up to 30% and cuts costs 10-15%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche bundles pharma+diagnostics for precision medicine, driving improved response rates (up to 30% in 2024 oncology studies) and 10-15% lower downstream costs; 2024 sales: Pharmaceuticals CHF 48.9bn, Diagnostics CHF 26.5bn, oncology sales CHF 28.4bn, diagnostics revenue CHF 16.2bn, 98% on-time shipment, 22% sales from emerging markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales\u003c\/td\u003e\n\u003ctd\u003eCHF 48.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics sales\u003c\/td\u003e\n\u003ctd\u003eCHF 26.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology sales\u003c\/td\u003e\n\u003ctd\u003eCHF 28.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics (reported)\u003c\/td\u003e\n\u003ctd\u003eCHF 16.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time shipment\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets share\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology response improvement\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDownstream cost reduction\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Professional Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche sustains high-touch ties with oncologists, pathologists and lab managers via ~1,800 medical science liaisons (MSLs) globally who deliver technical data and clinical support for complex therapies and diagnostics; in 2024 Roche reinvested CHF 15.7bn in R\u0026amp;D (20% of sales) to back this consultative model, which helped drive Roche Pharma sales of CHF 33.5bn and maintain \u0026gt;70% repeat prescribing in core oncology accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cproche runs patient support programs offering financial aid and education to improve adherence access therapies in roche reported million interactions globally through these services helping reduce treatment discontinuation by an estimated oncology cohorts.\u003e\n\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Institutional Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche signs multi-year contracts with hospital systems and lab chains for diagnostics and pharma logistics, often bundling equipment, consumables, maintenance and staff training; in 2024 Roche Diagnostics reported about CHF 18.5bn revenue, with institutional sales driving repeat orders and service margins. These integrated agreements raise switching costs and produced predictable annuity-like revenue-service and consumables account for roughly 40% of diagnostics segment sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cproche digital portals give healthcare providers access to clinical data product info and ordering cutting order cycle times helping manage inventory in roche reported over million engagements monthly across its platforms. channels streamline interactions updates on new diagnostics therapies built-in feedback loops feed improvement pharmacovigilance processes.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 access to clinical data and ordering\u003c\/li\u003e\n\u003cli\u003e1.2 million+ monthly digital engagements (2024)\u003c\/li\u003e\n\u003cli\u003eImproved inventory management and faster order cycles\u003c\/li\u003e\n\u003cli\u003eContinuous feedback for product improvement and safety\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Clinical Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche partners with leading clinicians as principal investigators across ~6,000 active global trials (2024), letting doctors access cutting-edge science while Roche gains real-world clinical insights that inform development and regulatory filings.\u003c\/p\u003e\n\u003cp\u003eThese collaborations produce peer-reviewed papers-Roche authors\/co-authors appeared on ~1,200 publications in 2023-strengthening product credibility and supporting market uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~6,000 active trials (2024)\u003c\/li\u003e\n\u003cli\u003e~1,200 Roche-linked publications (2023)\u003c\/li\u003e\n\u003cli\u003edrives regulatory evidence and commercial adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's high‑touch ecosystem: 1.8k MSLs, 1.2M monthly digital touches, 6k trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche maintains consultative, high-touch relationships via ~1,800 MSLs, multi-year institutional contracts and digital portals (1.2M+ monthly engagements in 2024), plus patient support programs (3.1M interactions in 2024), driving repeat prescribing (\u0026gt;70% in oncology), stable diagnostics annuities (service\/consumables ~40% of segment sales) and evidence generation from ~6,000 trials (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSLs\u003c\/td\u003e\n\u003ctd\u003e~1,800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital engagements\/month\u003c\/td\u003e\n\u003ctd\u003e1.2M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient interactions\u003c\/td\u003e\n\u003ctd\u003e3.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology repeat prescribing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics service share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trials\u003c\/td\u003e\n\u003ctd\u003e~6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche's primary channel to hospitals and specialist physicians is a highly trained internal sales force that details clinical benefits and negotiates large-scale diagnostic contracts; in 2024 Roche spent CHF 6.9bn on selling, general and administrative expenses, much of which supports this team, and field reps drive \u0026gt;60% of hospital formulary decisions via tailored, real-time engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn many markets Roche uses third-party specialized medical distributors with local regulatory know-how and logistics to reach small clinics and remote areas, expanding reach without heavy local infrastructure; by 2024 Roche reported ~45% of its diagnostics and pharma sales overseas relied on distributor networks, helping sustain ≈CHF 55.8B group sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Clinical and Diagnostic Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche delivers diagnostic results and clinical decision support via online portals to healthcare providers, forming the primary channel for the software part of its value proposition; by 2024 Roche Digital reported \u0026gt;€1.2bn in connected diagnostics revenue, speeding report turnaround by up to 40% in pilot hospitals. These portals improve clinician workflow and decision-making with real-time data and integrated analytics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Laboratory Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial diagnostic laboratory chains serve as key intermediaries by running high-volume testing on Roche systems, driving reagent and assay consumption across hospitals, clinics, and direct-to-consumer services; in 2024 Roche Diagnostics reported ~53% of group sales, with core lab instruments central to that revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume placement → recurring reagent sales\u003c\/li\u003e\n\u003cli\u003e2024: Diagnostics ~53% of Roche group sales\u003c\/li\u003e\n\u003cli\u003eScales assays across multiple end-customers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Hospital Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche distributes prescription medicines via global retail and hospital pharmacies, leveraging \u0026gt;1.2 million community pharmacies worldwide to ensure broad patient access and adherence to therapy.\u003c\/p\u003e\n\u003cp\u003eClose coordination with pharmacy networks supports stock availability, dispensing accuracy, and patient education-critical for specialty oncology and immunology drugs where Roche reported CHF 34.1 billion sales in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach: \u0026gt;1.2M pharmacies\u003c\/li\u003e\n\u003cli\u003e2024 pharma sales: CHF 34.1B\u003c\/li\u003e\n\u003cli\u003eFocus: availability, safe dispensing, patient education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's multi-channel reach: diagnostics-led sales, CHF 34.1bn pharma, €1.2bn digital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche uses a trained internal sales force for hospitals (\u0026gt;60% formulary influence) and CHF 6.9bn SG\u0026amp;A (2024); third-party distributors cover ~45% overseas sales; digital portals (Roche Digital) generated \u0026gt;€1.2bn (2024); diagnostics ~53% of group sales; pharma CHF 34.1bn (2024) via \u0026gt;1.2M pharmacies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal sales force\u003c\/td\u003e\n\u003ctd\u003eCHF 6.9bn SG\u0026amp;A; \u0026gt;60% hospital influence\u003c\/td\u003e\n\u003ctd\u003eDrives large contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~45% overseas sales\u003c\/td\u003e\n\u003ctd\u003eExtends reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e€1.2bn revenue\u003c\/td\u003e\n\u003ctd\u003eFaster reports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e~53% group sales\u003c\/td\u003e\n\u003ctd\u003eRecurring reagent demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma pharmacies\u003c\/td\u003e\n\u003ctd\u003eCHF 34.1bn; \u0026gt;1.2M pharmacies\u003c\/td\u003e\n\u003ctd\u003eBroad patient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and Specialized Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMajor medical centers and specialized oncology clinics are primary users of Roche's high-end biologics and integrated lab systems, buying products that drive clinical efficacy in complex cancers; in 2024 hospitals accounted for roughly 48% of Roche Pharma \u0026amp; Diagnostics institutional sales (~CHF 29.6 billion of CHF 61.7 billion total), prioritizing therapies that improve survival in advanced, life‑threatening conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Diagnostic Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge-scale private commercial diagnostic laboratories drive Roche Diagnostics' high-volume sales, demanding high-throughput analyzers and low-cost reagents; in 2024 Roche Diagnostics reported CHF 18.8 billion in sales, with core lab systems and consumables a major contributor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpnational health systems and ministries of buy roche diagnostics medicines for national screening essential drug programs often via tenders in reported billion revenue with pharma sales key to large-scale procurement. these customers prioritize public-health outcomes cost-effectiveness-e.g. who-led targets can drive multi-year contracts worth tens hundreds millions so economic value population impact guide procurement decisions.\u003e\n\u003c\/pnational\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUniversities and private research organizations buy Roche diagnostic instruments and reagents for basic and applied research; while they account for a small share of Roche Diagnostics revenue (estimated \u0026lt;5% of Roche's CHF 43.5B Diagnostics sales in 2024), they drive innovation and pipeline insights that enable future clinical products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvide early feedback that leads to clinical assays\u003c\/li\u003e\n\u003cli\u003eSupport validation studies and publications (thousands\/year)\u003c\/li\u003e\n\u003cli\u003eSmaller direct revenue but high strategic value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpindividual patients with chronic diseases notably the million people diabetes globally in are direct consumers of roche monitoring devices and prioritize simplicity clinical-grade accuracy seamless mobile app integration for daily self-management.\u003e\n\u003cpmarketing must shift to ux-focused campaigns subscription models and patient support-roche diabetes care reported revenue in so targeting retention app engagement can lift arpu reduce device churn.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect consumers: diabetes (537M worldwide, 2023)\u003c\/li\u003e\n\u003cli\u003eKey needs: ease of use, accuracy, app data sync\u003c\/li\u003e\n\u003cli\u003eMarketing: UX, subscriptions, patient support\u003c\/li\u003e\n\u003cli\u003eFinancials: Roche Diabetes Care ~CHF 1.6bn revenue (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmarketing\u003e\u003c\/pindividual\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's CHF55B+ reach: hospitals, labs, health systems, research \u0026amp; diabetes patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche serves hospitals\/oncology centers (≈48% institutional sales; CHF 29.6B of CHF 61.7B, 2024), large private labs (Roche Diagnostics CHF 18.8B, 2024), national health systems (driving multi‑year tenders; Roche total revenue ≈CHF 55.3B, 2024), research orgs (\u0026lt;5% of Diagnostics ≈CHF 2.2B est., 2024) and individual patients (diabetes care ≈CHF 1.6B, 2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCustomer\u003c\/th\u003e\n\u003cth\u003e2023-24 revenue\/size\u003c\/th\u003e\n\u003cth\u003eKey need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Oncology\u003c\/td\u003e\n\u003ctd\u003eCHF 29.6B (48% of institutional, 2024)\u003c\/td\u003e\n\u003ctd\u003eClinical efficacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate labs\u003c\/td\u003e\n\u003ctd\u003eCHF 18.8B (Diagnostics, 2024)\u003c\/td\u003e\n\u003ctd\u003eHigh throughput\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth systems\u003c\/td\u003e\n\u003ctd\u003eDrives tenders; Roche rev CHF 55.3B (2024)\u003c\/td\u003e\n\u003ctd\u003eCost-effectiveness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5% Diagnostics ≈CHF 2.2B est. (2024)\u003c\/td\u003e\n\u003ctd\u003eInnovation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients (diabetes)\u003c\/td\u003e\n\u003ctd\u003eCHF 1.6B (Diabetes Care, 2023); 537M people (2023)\u003c\/td\u003e\n\u003ctd\u003eSimplicity, accuracy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche's largest cost driver is R\u0026amp;D-covering drug discovery, clinical trials, and diagnostics innovation-and the group reinvested CHF 11.7 billion in R\u0026amp;D in 2024, about 19% of sales, underscoring high-risk, high-return spending to protect its scientific leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of complex biologics and precision diagnostics at Roche (Roche Holding AG, 2025 revenue CHF 64.8bn) drives high costs from specialty raw materials, GMP-grade facilities, and clean-room energy use; maintaining 30+ global manufacturing sites and cold-chain logistics pushes COGS and capex (Roche 2024 capex CHF 2.7bn). Efficient operations and continuous process optimization are vital to protect margins against pricing pressure and biosimilar competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, General, and Administrative\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cproche sg covers global sales force payroll marketing campaigns and corporate overhead in roche reported chf billion operating expenses with roughly of that funding product adoption across markets.\u003e\n\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and compliance costs force Roche to spend heavily on global quality control and legal teams; in 2024 Roche reported R\u0026amp;D and regulatory-related operating expenses contributing to its CHF 16.5bn R\u0026amp;D spend, with approvals filing and maintenance often costing tens of millions per asset.\u003c\/p\u003e\n\u003cp\u003eNoncompliance risks fines and recalls-e.g., industry precedent fines \u0026gt;$1bn-and drive ongoing surveillance and reporting costs that add materially to per-product lifecycle expenses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing compliance staffing and systems: tens of millions per year\u003c\/li\u003e\n\u003cli\u003ePer-drug approval filing and maintenance: often $10-100m+\u003c\/li\u003e\n\u003cli\u003eIndustry fines\/recalls precedent: \u0026gt;$1bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Data Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cproche shift to personalized healthcare has raised annual digital and data infrastructure spend-roche reported chf in r it investments by cloud costs cybersecurity software development store analyze petabytes of genomic clinical data.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e2024 digital spend: CHF 1.6bn reported\u003c\/li\u003e\n\u003cli\u003eData scale: petabytes of genomic\/clinical data\u003c\/li\u003e\n\u003cli\u003eKey costs: cloud, security, SW dev\u003c\/li\u003e\n\u003cli\u003eStrategic value: enables diagnostics-drug integration\u003c\/li\u003e\n\n\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche cost breakdown: R\u0026amp;D CHF11.7bn, capex CHF2.7bn, Opex CHF18.2bn, digital CHF1.6bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's main costs are R\u0026amp;D (CHF 11.7bn in 2024, ~19% of sales), manufacturing \u0026amp; cold-chain capex (2024 capex CHF 2.7bn; 30+ sites), SG\u0026amp;A (~22% of CHF 18.2bn operating expenses in 2024), regulatory\/legal (per-asset filing $10-100m+, industry fines \u0026gt;$1bn precedent), and digital\/data (CHF 1.6bn in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eCHF 11.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003eCHF 2.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating expenses\u003c\/td\u003e\n\u003ctd\u003eCHF 18.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital spend\u003c\/td\u003e\n\u003ctd\u003eCHF 1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical product sales make up roughly 70% of Roches 2024 group revenue, driven by high-margin oncology and immunology drugs like Ocrevus and Tecentriq; these products are sold worldwide to hospitals and pharmacies and benefited from 3-5% organic sales growth in 2024 due to clinical differentiation and ongoing patent protection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics Equipment Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche earned about CHF 7.1 billion from its Diagnostics division in 2024, driven largely by capital sales and leasing of instruments to hospitals and labs, which create long-term service contracts and consumables demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReagents and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche earns high-margin, recurring revenue from proprietary reagents and consumables that customers must buy after installing diagnostic instruments; in 2024 Roche Diagnostics reported about 28.2 billion CHF in diagnostics-related sales, with consumables driving ~60% of segment revenue, giving predictable cash flow and strong visibility into future earnings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche earns revenue by licensing proprietary technologies and molecular assets to pharma and biotech partners, collecting royalties on products using Roche patents and early-stage research; in 2024 Roche reported CHF 1.31bn in licensing and royalty income, ~2.6% of Group sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing income CHF 1.31bn (2024)\u003c\/li\u003e\n\u003cli\u003e~2.6% of 2024 Group sales\u003c\/li\u003e\n\u003cli\u003eMonetizes IP without full development risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Service Subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche now earns growing SaaS revenue from clinical decision support and data-analytics platforms, with subscription fees from labs and hospitals for workflow and patient-data management; digital offerings contributed about CHF 1.2 billion in 2024, up ~18% vs 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 1.2bn digital revenue (2024)\u003c\/li\u003e\n\u003cli\u003e~18% year-over-year growth (2024 vs 2023)\u003c\/li\u003e\n\u003cli\u003eSaaS for labs\/hospitals: subscription fees\u003c\/li\u003e\n\u003cli\u003eSupports workflow, patient-data, clinical decision tools\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche 2024: Pharma ~70% led by oncology, Diagnostics CHF28.2bn, Digital +18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's 2024 revenues: Pharma ~70% driven by oncology\/immunology (3-5% organic growth); Diagnostics CHF 28.2bn with consumables ~60%; Licensing CHF 1.31bn (~2.6%); Digital\/SaaS CHF 1.2bn (+18% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e~70% group\u003c\/td\u003e\n\u003ctd\u003eOcrevus, Tecentriq; 3-5% organic growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eCHF 28.2bn\u003c\/td\u003e\n\u003ctd\u003eConsumables ~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eCHF 1.31bn\u003c\/td\u003e\n\u003ctd\u003e~2.6% group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/SaaS\u003c\/td\u003e\n\u003ctd\u003eCHF 1.2bn\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"VRIO Analysis","offers":[{"title":"Default Title","offer_id":57515147002188,"sku":"roche-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1056\/0356\/3852\/files\/roche-canvas-business-model.webp?v=1778639831","url":"https:\/\/vrio-analysis.com\/products\/roche-business-model-canvas","provider":"VRIO Analysis","version":"1.0","type":"link"}